Patrys Limited
ASX:PAB.AX
Overview | Financials
Company Name | Patrys Limited |
Symbol | PAB.AX |
Currency | AUD |
Price | 0.003 |
Market Cap | 6,172,350 |
Dividend Yield | 0% |
52-week-range | 0.003 - 0.011 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. James A. Campbell B.Sc., MBA, Ph.D. |
Website | https://www.patrys.com |
An error occurred while fetching data.
About Patrys Limited
Patrys Limited, together with its subsidiaries, develops and commercializes antibody technologies for the treatment of cancer in Australia. Its lead technology is Deoxymab 3E10, a DNA damage-repair antibody that penetrates cell nuclei. The company also focuses on developing PAT-DX1, an antibody fragment for the treatment of primary and secondary brain
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD